Healio Gastroenterology presents the following account of our latest inflammatory bowel disease coverage.

These stories include topics regarding COVID-19 and IBD, therapeutic research, a preview of the ACG Annual Scientific Meeting and more.

Though there is no significant difference in COVID-19 infection rates among patients with inflammatory bowel disease compared with the general public, some IBD therapies correlated with increased infection severity.

“The therapies for IBD are predominantly immune-based, immune modifying and sometimes immune suppressive,” David T. Rubin, MD, FACG,

Full Article: https://www.healio.com/news/gastroenterology/20210910/7-recent-reports-on-ibd